当前位置: X-MOL首页全球导师 国内导师 › 饶贤才

个人简介

学习经历 2007.03-2008.11 美国波士顿大学医学院 博士后 1999.09-2002.12 第三军医大学微生物学 博士生 1992.09-1995.07 第三军医大学微生物学 硕士生 1986.09-1990.07 第三军医大学医学检验专业 本科 工作经历 2018.01-今 陆军军医大学微生物学教研室 主任,教授 2010.07-2017.12 第三军医大学微生物学教研室 主任,教授 2006.09-2010.06 第三军医大学微生物学教研室 副主任,教授 2001.09-2006.08 第三军医大学微生物学教研室 副主任,副教授 1996.09-2001.08 第三军医大学微生物学教研室 讲师 1990.08-1996.08 第三军医大学微生物学教研室 助教 教授课程:1.《医学微生物学》(通讲) 2.《实验室安全与防护》(研究生课程,教学组长) 3.《生命科学综合Ⅳ:生物医学前沿技术》(研究生课程,组长) 4.《分子微生物学》(研究生课程) 2.专利 1) 饶贤才,袁吉振、杨杰、胡珍、杨裔,胡启文,尚伟龙,朱军民。一种金黄色葡萄球菌膜泡展示系统及其制备方法和应用,专利号:ZL201510945536.5, 2019授权 2) 饶贤才,袁吉振、杨杰、胡珍、胡晓梅、陈炜. 金黄色葡萄球菌突变株及其制备方法和应用. 专利号:ZL 201310286005.0 2014授权 3) 饶贤才;杨杰;胡珍;胡晓梅;陈炜.一种登革病毒简并疫苗及其应用. 专利号:ZL 201310140259.1 , 2014授权 4) 饶贤才,杨杰,张俊磊,胡珍,方昕,袁文常. 登革病毒亚单位疫苗及其制备方法. 国家发明专利. 201110112898.8 2011.5.4 5) 饶贤才,胡福泉,胡珍,朱军民,陈志瑾,杨杰 登革病毒-日本脑炎病毒嵌合假病毒疫苗及其制备方法 申请号201010212602.5,2012授权 6) 胡福泉,卢曙光,李明,乐率,饶贤才. 大肠杆菌DH5α的nfi基因敲除突变株及其制备方法和应用,专利号:ZL 201010600832.9 2013授权 7) 胡晓梅,胡福泉,饶贤才,李欢,一种用于肿瘤局部介入治疗的TAT-PEIII融合蛋白及制备方法。申请号:200710092463.5 8) 胡福泉,饶贤才,黎庶,胡金川. 多拷贝串联人肽抗生素hPAB的制备 申请号:2004100075343 9) 饶贤才,胡福泉. 一种高效表达生产肽抗生素的方法. 专利号:ZL 01131855。2004年授权 3.承担的项目 1) 军队XXXX重大项目:“XXXXX免疫筛查分析技术与产品研究”,2017.10-2020.12.课题编号17SAZ08,经费1000万元(主持). 2) 基础-临床融合研究项目:“琥珀酰化修饰影响金黄色葡萄球菌中等耐受万古霉素中的作用与机制”. 2019.12-2022.11.课题编号:2019JCLC01,经费20万元(主持) 3) 国家重点研发专项“重要病原体的现场快速多模态谱学识别与新型杀灭技术”子课题“电磁-新材料复合式病原体杀灭的机理研究”,子课题编号:2017YFC1200404-4,经费190万元,2017.10-2020.12(负责人) 4) 国家自然科学基金:WalKR通过CcpA调控万古霉素中介耐药金黄色葡萄球菌致病性的机制研究,编号81672071,2017.1-2020.12,57万元,(负责人) 5) 校科技成果转化基金:登革热膜泡疫苗的工艺放大.编号2016XZH01; 2017.1-2019.12, 50万元(负责人) 6) 国家自然科学基金:磷壁酸合成途径在万古霉素中介金黄色葡萄球菌向高耐药菌转化中的作用与机制,编号:81471993;2015-1-2018.12, 72万元(负责人) 7) 教育部回国人员启动基金:噬菌体MmP1早期基因的鉴定及其在寄生宿主中作用研究,2013.01~2014.12,3万元(负责人) 8) 国家自然科学基金:重组登革膜泡疫苗的构建及其免疫效能研究. 编号:31270979,2013.1-2013.12;15万元(负责人) 9) 国家科技重大专项:登革热膜泡疫苗的研制,课题编号2012ZX09103301-038, 经费132.62万,2012.1-2015.12(负责人) 10) 国家自然科学基金:新基因pbpR负调控金黄色葡萄球菌耐药性的作用与机制研究,编号:81171622,2012.1-2015.12,58万(负责人) 11) 军队XXX重大专项子课题:重要蚊传黄病毒致病机制及嵌合假病毒研究,编号:AWS11J011-07,经费150万,2011.1-2015.12(负责人) 12) 国家自然科学基金:登革-日本脑炎嵌合假病毒自组装颗粒的构建及免疫效能研究.编号:31070811,2011.1-2013.12,经费30万元(负责人) 13) 校回国启动基金:登革病毒包膜E蛋白相互作用分子的筛选与鉴定;编号2009XHG03,2009.8-2011.8,经费5万元(负责人) 14) 校预研基金:双表位D-J假病毒自组装颗粒的研制,编号2009XYY04,2009.8-2010.12,经费20万元(负责人) 15) 重庆市自然科学基金:人内皮细胞登革病毒受体的筛选研究,编号CSTC,2009BB5015,2009.6.9-2012.6.9,经费3.0万元(负责人) 16) 国家自然科学基金:肽抗生素hPAB-β抗细菌L型感染的实验研究,编号30772061, 2008.1-2010.12,经费30万元(负责人) 17) 国家自然科学基金:抗耐药金黄色葡萄球菌嵌合药靶的设计与构建,编号30571666,2006.1-2008.12.经费26万元(负责人) 18) 国家自然科学基金:人源肽抗生素hPAB-β突变体的构建与筛选.编号30171119,2002.01-2004.12,经费17.00万元(负责人) 19) 国家“863”课题:人体基因编码的肽抗生素的开发研究.编号2002AA214211, 2002.11-2004.12,经费60.00万元(负责人). 20) 重庆市重点课题:人源性抗菌肽hBD-2的开发研究,编号CSTC.20006315. 2000.6-2002.12,经费10.00万元(负责人) 21) 校科研基金:肺炎衣原体种特异性抗原基因的克隆与表达,1998.09~2000.12,经费2.0万元(负责人). 4.获奖 1) 袁吉振,饶贤才.减毒金黄色葡萄球菌膜泡递送系统的构建及其在多价登革热膜泡疫苗制备中的应用. 全军优秀博士论文,2020 2) 刘慧,饶贤才.SigB(Q225P)突变促进金黄色葡萄球菌生物被膜形成的作用与机制研究.重庆市优秀硕士论文.2019 3) 府伟灵,韩黎,饶贤才,毛远丽,夏涵,姚春艳,胡晓梅,韩雪琳,罗阳,胡川闽,黄庆,李伯安,黄君富,张波,王云霞. 医院感染防控体系构建及关键技术研究.华夏医学科技三等奖,2016.11 4) 程航,饶贤才.耐甲氧西林金黄色葡萄球菌临床分离株的分子分型及耐药性分析.重庆市优秀硕士论文.2015 5) 陈鸣,饶贤才,王云霞,邓少丽,鲁卫平,徐清华,唱 凯,贾双荣,胡晓梅:野战环境下病原微生物漏声表面波传感器阵列及分子生物学检测技术的建立。2013军队科技进步二等奖 6) 胡福泉,饶贤才,胡金川,黎庶,金晓琳,胡晓梅,朱军民,陈志瑾,张椿完成的“肽抗生素hPAB-β突变体的构建与活性研究”获2007年军队科技进步二等奖。 7) 饶贤才,俞树荣,朱瑾,胡福泉,张光明,胡晓梅,张克斌.肺炎衣原体感染检测的研究,2000年军队科技进步三等奖。

研究领域

研究方向:微生物致病机理与耐药性。重点针对多耐药金黄色葡萄球菌耐药性,尤其是万古霉素耐药性开展研究,针对金葡菌和登革病毒的致病机理进行研究,探讨病原与宿主相互作用,建立抗感染防治新手段。

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

论文(通讯作者或第一作者) 1) Yang Y, Shang W,Rao X.Facing the COVID-19 outbreak: What should we know and what could we do? J Med Virol.2020; 92(6):536-537. (IF 2.012) 2) Shang W, Yang Y, Rao Y,Rao X.The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. npj vaccines. 2020; 5:18.(IF 5.699) 3) Yang Y, Wang H, Zhou H, Hu Z, Shang W, Rao Y, Peng H, Zheng Y, Hu Q, Zhang R, Luo H,Rao X.Protective effect of the golden staphyloxanthin biosynthetic pathway on Staphylococcus aureus under cold atmospheric plasma treatment. Appl Environ Microbiol. 2020: 86(3): e01998-19 (IF 4.016) 4) Cong Y, Yang S,Rao X.Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J Adv Res. 2020:21:169-176 (IF 6.992) 5) Shang W, Rao Y, Zheng Y, Yang Y, Hu Q, Hu Z, Yuan J, Peng H, Xiong K, Tan L,Li S, Zhu J, Li M, Hu X, Mao X,Rao X. β-Lactam antibiotics enhance the pathogenicity of methicillin-resistantStaphylococcus aureus via SarA-controlled lipoprotein like cluster expression. mBio. 2019;10(3): e00880-19.(IF 6.782) 6) Zheng Y, Shang W, Peng H, Rao Y, Zhao X, Hu Z, Yang Y, Hu Q, Tan L, Xiong K, Li S, Zhu J, Hu X, Zhou R, Li M,Rao X.Virulence determinants are required for brain abscess formation through Staphylococcus aureusInfection and are potential targets of antivirulence factor therapy. Front Microbiol. 2019;10:682.(IF 4.235) 7) Peng H, Rao Y, Yuan W, Zheng Y, Shang W, Hu Z, Yang Y, Tan L,Xiong K, Li S, Zhu J, Hu X, Hu Q,Rao X. Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108. Front. Microbiol. 2018; 9: 2955.(IF 4.259) 8) Liu H, Shang W, Hu Z, Zheng Y, Yuan J, Hu Q, Peng H, Cai X, Tan L, Li S, Zhu J, Li M, Hu X, Zhou R,Rao X, Yang Y.A novel SigB(Q225P) mutation inStaphylococcus aureusretains virulence but promotes biofilm formation. Emerg Microbes Infec. 2018;7(1):72. (IF 6.212) 9) Yang Y, Yang J,Rao X.What role does superficial vimentin have during DENV-2 infection? Future Virol 2018; 13(3):151-154(IF 1.121) 10) Yuan J, Yang J, Hu Z, Yang Y, Shang W, Hu Q, Zheng Y, Peng H, Zhang X, Cai X, Zhu J, Li M, Hu X, Zhou R,Rao X.Safe staphylococcal platform for the development of multivalent nanoscale vesicles against viral infections. Nano Lett.2018;18(2):725-733. (IF 12.279) 11) Yu H,Rao X, Zhang K.Nucleoside diphosphate kinase (Ndk): A pleiotropic effector manipulating bacterial virulence and adaptive responses. Microbiol Res. 2017;205:125-134.(IF 2.777) 12) Zhang X, Hu X,Rao X.Apoptosis induced by Staphylococcus aureus toxins. Microbiol Res. 2017; 205:19-24.(IF 2.777) 13) Li M, Shen X, Zhao Y, Hu X, Hu F,Rao X. Better understanding of homologous recombination through a 12-week laboratory course for undergraduates majoring in biotechnology. Biochem Mol Biol Educ. 2017;45(4):329-335. (IF 1.036) 14) Peng H, Hu Q, Shang W, Yuan J, Zhang X, Liu H, Zheng Y, Hu Z, Yang Y, Tan L, Li S, Hu X, Li M,Rao X. WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.J Antimicrob Chemother. 2017;72(4):1006-1013.(IF,5.217) 15) Yang Y, Hu Z, Shang W, Hu Q, Zhu J, Yang J, Peng H, Zhang X, Liu H, Cong Y, Li S, Hu X, Zhou R,Rao X.Molecular and phenotypic characterization revealed high prevalence of multidrug-resistant methicillin-susceptible Staphylococcus aureus in Chongqing, Southwestern China. Microb Drug Resist.2017;23(2):241-246. (IF 2.344) 16) Yang J, Zou L, Yang Y, Yuan J, Hu Z, Liu H, Peng H, Shang W, Zhang X, Zhu J,Rao X.Superficial vimentin mediates DENV-2 infection of vascular endothelial cells. Sci Rep. 2016;6:38372.(IF=5.228) 17) Hu Q, Peng H,Rao X.Molecular events for promotion of vancomycin resistance in vancomycin intermediate Staphylococcus aureus. Front Microbiol. 2016;7:1601. (IF 4.076) 18) Zhang X, Shang W, Yuan J, Hu Z, Peng H, Zhu J, Hu Q, Yang Y, Liu H, Jiang B, Wang Y, Li S, Hu X,Rao X. Positive feedback cycle of TNFα promotes staphylococcal enterotoxin B-induced THP-1 cell apoptosis. Front Cell Infect Microbiol. 2016;6:109. (IF 5.218) 19) Li M, Hu X, Hu F,Rao X.Beyond the classroom lecture: Liang Wang's personal war on tuberculosis in China. Protein Cell. 2016;7(10):697-698. (IF 5.374) 20) Liu H, Zhu J, Hu Q,Rao X.Morganella morganii, a non-negligent opportunistic pathogen. Int J Infect Dis. 2016;50:10-17. (IF 2.532) 21) Yu H,Xiong J,Zhang R,Hu X,Qiu J,Zhang D,Xu X,Xin R,He X,Xie W,Sheng H,Chen Q,Zhang L,Rao X,Zhang K. Ndk, a novel host-responsive regulator, negatively regulates bacterial virulence through quorum sensing in Pseudomonas aeruginosa.Sci Rep. 2016; 6:28684. (IF 4.259) 22) Rao Q, Shang W, Hu X,Rao X. Staphylococcus aureus ST121: A globally disseminated hypervirulent clone. J Med Microbiol 2015; 64(12):1462-73. (IF 2.269) 23) Shang W, Hu Q, Yuan W, Cheng H, Yang J, Hu Z, Yuan J, Zhang X, Peng H, Yang Y, Hu X, Li M, Zhu J,Rao X. Comparative fitness and determinants for the characteristic drug resistance of ST239-MRSA-III-t030 and ST239-MRSA-III-t037 strains isolated in China. Microb Drug Resist.2016; 22(3):185-92. (IF 2.306) 24) Xiong K, Chen Z, Zhu C, Li J, Hu X,Rao X, Cong Y.Safety and immunogenicity of an attenuated Salmonella enterica serovar Paratyphi A vaccine candidate. Int J Med Microbiol.2015; 305(6):563-71 (IF 3.898) 25) Rao Q, Shang W, Zhou K,Zhou R,Rao X, Fatalmultiple organ failure in anadolescentdue to community-acquired methicillin- susceptible Staphylococcus aureus ST121/agrIV lineage: case report and review. Rev Med Microbiol.2015, 26(4): 163–167. (IF0.75) 26) Hu Q, Cheng H, Yuan W, Zeng F, Shang W, Tang D, Xue W, Fu J, Zhou R, Zhu J, Yang J, Hu Z, Yuan J, Zhang X, Rao Q, Li S, Chen Z, Hu X, Wu X,Rao X.Panton—Valentine leukocidin (PVL)-positive healthcare-associated methicillin-resistantStaphylococcus aureus isolates are associated with skin and soft tissue infections and colonized mainly by infective PVL-encoding bacteriophages.J Clin Microbiol.2015;53(1):67-72. (IF 3.631) 27) Zhang X, Xu X, Yuan W, Hu Q, Shang W, Hu X, Tong Y,Rao X. Complete Genome Sequence ofStaphylococcus aureus XN108, an ST239-MRSA-III strain with Intermediate-Level Vancomycin Resistance Isolated in Mainland China. Genome Announc. 2014, 2(4):e00449-14. 28) Zhang X, Hu Q, Yuan W, Shang W, Cheng H, Yuan J, Zhu J, Hu Z, Li S, Chen W, Hu X,Rao X. First report of a sequence type 239 vancomycin-intermediate Staphylococcus aureus isolate in Mainland China, Diagn Microbiol Infec Dis2013;77(1):64-8.(IF 2.568) 29) Cheng H, Yuan W, Zeng F, Hu Q, Shang W, Tang D, Xue W, Fu J, Liu J, Liu N, Zhu J, Yang J, Hu Z, Yuan J, Zhang X, Li S, Chen Z, Hu X,Rao X. Molecular and phenotypic evidence for the spread of three major methicillin-resistant Staphylococcus aureus clones associated with two characteristic antimicrobial resistance profiles in China.J Antimicrob Chemother. 2013;68(11):2453-7.(IF 2013 5.439) 30) Yang J, Zou L, Hu Z, Chen W, Zhang J, Zhu J, Fang X, Yuan W, Hu X, Hu F,Rao X. Identification and characterization of a 43 kDa actin protein involved in the DENV-2 binding and infection of ECV304 cells.Microbes Infect. 2013;15(4):310-318.(IF2013 2.731) 31) Yuan W, Hu Q, Cheng H, Shang W, Liu N, Hua Z, Zhu J, Hu Z, Yuan J, Zhang X, Li S, Chen Z, Hu X, Fu J,Rao X.Cell wall thickening is associated with adaptive resistance to amikacin in methicillin-resistant Staphylococcus aureus clinical isolates. J Antimicrob Chemother. 2013;68(5):1089-1096, (IF 5.439) 32) Fang X,Hu Z,Shang W,Zhu J,Xu C,Rao X. Genetic polymorphisms of molecules involved in host immune response for Dengue virus infection. FEMS Immunol Med Microbiol 2012;66(2):134-46 (IF 2.684) 33) Shang W, Liu J, Hu Z, Yang J,Zhu J,Rao X. Dengue virus-like particles: construction and application. Appl Microbiol Biotech. 2012,94(1):39-46.(IF 3.689) 34) Yang J, Zhang J, Chen W, Hu Z, Zhu J, Fang X, Yuan W, Li M, Hu X, Tan Y, Hu F, andRao X. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli. Can J Microbiol. 2012; 58(4):369-80.(IF 1.199) 35) Wang D, Chen Z, Hu Z, Yuan W,Rao X. A recombinant antimicrobial peptide inhibits the growth of oxacillin-induced L-forms of Staphylococcus aureus.Int J Antimicrob Ag. 2011;38(2):177-178.IF 4.128) 36) Chen Z, Wang D, Cong Y, Wang J, Zhu J, Yang J, Hu Z, Hu X, Tan Y, Hu F,Rao X. Recombinant antimicrobial peptide hPAB-β expressed in Pichia pastoris, a potential agent active against methicillin resistant Staphylococcus aureus.Appl Microbiol Biot. 2011;89(2):281-291. (IF 3.280) 37) Zhu J, Rao X, Tan Y, Xiong K, Hu Z, Chen Z, Jin X, Li S, Chen Y, Hu F. Identification of a lytic Bacteriophage MmP1, assigned to a new member of T7-like phages infecting Morganella morganii. Genomics, 2010;96:167-172 (共同第一,IF 4.087) 38) Rao X, Deighan P, Hua Z, Hu X, Wang J, Luo M, Wang J, Liang Y, Zhong G, Hochschild A, Shen L. A regulator from Chlamydia trachomatis modulates the activity of RNA polymerase through direct interaction with the β subunit and the primary σ subunit. Genes Dev. 2009, 23(15): 1818-1829. (IF 13.623) 39) Rao X, Hu J, Li S, Jin X, Zhang C, Cong Y, Hu X, Tan Y, Huang J, Chen Z, Zhu J, Hu F. Design and expression of peptide antibiotic hPAB-β as tandem multimers inE. coli. Peptides. 2005; 26(5): 721-729. (IF 2.635) 40) Rao XC, Li S, Hu JC, Jin XL, Hu XM, Huang JJ, Chen ZJ, Zhu JM, Hu FQ. A novel carrier molecule for high-level expression of peptide antibiotics inEscherichia coli. Protein Expres Purify. 2004,36(1):11-16. (IF 1.47) 41) Rao XC, Hu XM, Jin XL, Huang JJ, Li S, Chen ZJ, Zhu JM, Hu JC, Hu FQ.Cpn0809 gene: another useful target for detection of Chlamydophila pneumoniae by PCR. Ann Microbiol, 2004;54(1):115-125. (IF 0.53)

推荐链接
down
wechat
bug